Bristol-Myers Squibb (BMY)

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

It notched convincing beats on analyst estimates with its second-quarter performance.

Things are going well for the pharmaceutical giant.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for. Bristol-Myers ...

Bristol Myers keeps making moves to establish a strong foundation for the future.

We may still be in the early innings of the AI revolution, and these companies could be among the biggest winners.

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

Analysts aren't nearly as bullish about Bristol Myers Squibb as this billionaire hedge fund manager is.

Sometimes you need to look beyond the numbers to get the full story.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...

Could it become as successful in this niche as it was in the coronavirus vaccine market?

Drug pricing matters, but pipelines matter even more.

They may not remain cheap for too much longer.

It doesn't get much more dependable and lucrative than the healthcare industry.

This big pharma stock looks attractive for income investors -- but it comes with some risk.

Strong productivity gains from AI -- and lower inflation -- could be good news for these Vanguard ETFs.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?

Learn how a vertical spread options strategy can help reduce risk, lock in gains, and stay invested in winning trades.